Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications

Starting soon · Phase 1

Conditions studied: Liver Transplant; Complications, Liver Diseases

In brief

The purpose of this study is to assess the safety of autologous Adipose-Derived Mesenchymal Stem Cell for use in End-Stage Liver Disease patients undergoing the creation of a duct-to-duct anastomosis during Living Donor Liver Transplantation.

Key facts

Study ID

NCT06649864

Run by

Mayo Clinic

People needed

20

Starts

2027-02-01

Expected to finish

2028-06-01

Last updated by the study team

2026-04-06

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Listed for liver transplantation
• Non-pediatric patients with a planned LDLT
• Ability to communicate with investigative staff
• Competence to give written informed consent
• Ability to comply with the entire study procedure
• All sexes and genders will be eligible for the study

You may not qualify if…

• Planned deceased donor liver transplantation
• Uncontrolled / unresolved local or systemic infection
• Body mass index > 40
• Planned pancreaticoduodenectomy or sleeve gastrectomy
• Anticipation of 3 biliary anastomoses (we will include those anticipated to have 1 or 2 biliary anastomoses as detailed below)
• Pregnancy or breastfeeding
• Non-liver cancers (we will include certain patients with primary liver cancer as detailed below)
• Treatment with any investigational drug / device within 60 days prior to study entry
• Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of AMSCs
• Patients who are employees or relatives of the investigator

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.